# EDGAR Filing Document

**Accession Number:** 0001997464
**File Stem:** 0001193125-26-230792
**Filing Date:** 2026-5
**Character Count:** 33779
**Document Hash:** 8789bc100dd56721563a39e97a469b81
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-230792.hdr.sgml**: 20260519

**ACCESSION NUMBER**: 0001193125-26-230792

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260519

**FILED AS OF DATE**: 20260519

**DATE AS OF CHANGE**: 20260519

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Marex Group plc
- **CENTRAL INDEX KEY:** 0001997464
- **STANDARD INDUSTRIAL CLASSIFICATION:** SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES [6200]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42020
- **FILM NUMBER:** 26998954

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 155 BISHOPSGATE
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** EC2M 3TQ
- **BUSINESS PHONE:** 44 2076 556000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 155 BISHOPSGATE
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** EC2M 3TQ

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO SECTION 13A-16 OR 15D-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of May 2026** 

**Commission File Number: 001-42020** 

## MAREX GROUP PLC
**(Translation of registrant's name into English)** 

---

| | |
|:---|:---|
| **155 Bishopsgate<br>London EC2M 3TQ<br>United Kingdom<br>+44 20 7655 6000** | **140 East 45th Street, 10th Floor<br>New York, New York 10017<br>(212) 618-2800** |

---

**(Address of Principal Executive Offices)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXPLANATORY NOTE** 

**Completion of Consent Solicitation for 6.404% Senior Notes due 2029; Entry into Fourth Supplemental Indenture** 

On May 18, 2026, Marex Group plc (the "Company") issued a press release announcing it has received the requisite consents from registered holders of its 6.404% Senior Notes due 2029 (the "Notes") to approve certain proposed amendments (the "Proposed Amendments") to the Senior Indenture, dated as of October 15, 2024, as supplemented by the First Supplemental Indenture, dated as of November 4, 2024 (together, the "Indenture"), each between the Company and Citibank, N.A., as the trustee (the "Trustee"), pursuant to the Company's previously announced solicitation of consents for the Notes (the "Consent Solicitation"). The Consent Solicitation expired at 5:00 p.m., New York City time, on May 15, 2026.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Following receipt of the requisite consents from holders of at least a majority of the aggregate outstanding principal amount of the Notes, on May 19, 2026, the Company and the Trustee entered into a fourth supplemental indenture to the Indenture (the "Fourth Supplemental Indenture") governing the Notes to give effect to the Proposed Amendments. The Fourth Supplemental Indenture amends the Indenture governing the Notes so as to permit a holding company of the Group that is incorporated in the UK overseas territory of Bermuda or other specified jurisdictions to assume the Company's obligations under the Notes and Indenture, and succeed to, and be substituted for, the Company as issuer and obligor under the Notes and the Indenture. The Fourth Supplemental Indenture became effective and operative immediately upon its execution.

The foregoing general description of the Fourth Supplemental Indenture is qualified in its entirety by reference to the full text of the Fourth Supplemental Indenture, a copy of which is attached hereto as Exhibit 4.1 and is incorporated herein by reference.

**EXHIBIT INDEX** 

The following exhibits are filed as part of this Form 6-K:

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 4.1 | [Fourth Supplemental Indenture, dated May 19, 2026, by and between Marex Group plc and Citibank, N.A., as the trustee](d39300dex41.htm) |
| 99.1 | [Press Release dated May 18, 2026](d39300dex991.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Marex Group plc (Registrant) | Marex Group plc (Registrant) |
| By: | /s/ Robert Irvin |
| Name: | Robert Irvin |
| Title: | Chief Financial Officer |

---

Dated: May 19, 2026

## Exhibit 4.1

**Exhibit 4.1** 

FOURTH SUPPLEMENTAL INDENTURE

Dated as of May 19, 2026

Supplementing that Certain

INDENTURE

Dated as of October 15, 2024

Between

MAREX GROUP PLC, *as Issuer*

and

CITIBANK, N.A., *as Trustee*

6.404% SENIOR NOTES DUE 2029

------

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| ARTICLE I. | ARTICLE I. | ARTICLE I. |
| DEFINITIONS | DEFINITIONS | DEFINITIONS |
|  SECTION 1.1 | Certain Terms Defined in the Indenture | 2 |
| ARTICLE II. | ARTICLE II. | ARTICLE II. |
| AMENDMENTS | AMENDMENTS | AMENDMENTS |
|  SECTION 2.1 | Amendment and Restatement of Section 2.10 of the First Supplemental Indenture | 2 |
|  SECTION 2.2 | New Section 2.12 of the First Supplemental Indenture | 3 |
| ARTICLE III. | ARTICLE III. | ARTICLE III. |
| MISCELLANEOUS | MISCELLANEOUS | MISCELLANEOUS |
|  SECTION 3.1 | Relationship with Indenture | 4 |
|  SECTION 3.2 | Trust Indenture Act Controls | 4 |
|  SECTION 3.3 | Governing Law | 4 |
|  SECTION 3.4 | Multiple Counterparts | 5 |
|  SECTION 3.5 | Severability | 5 |
|  SECTION 3.6 | Ratification | 5 |
|  SECTION 3.7 | Headings | 5 |
|  SECTION 3.8 | Effectiveness | 5 |
|  SECTION 3.9 | Concerning the Trustee | 6 |

---

i

------

FOURTH SUPPLEMENTAL INDENTURE

This Fourth Supplemental Indenture, dated as of May 19, 2026 (this "**Fourth Supplemental Indenture**"), by and between Marex Group plc, a public limited company incorporated under the laws of England and Wales with company number 05613060 (the "**Company**"), having its registered office at 155 Bishopsgate, London, EC2M 3TQ, United Kingdom, and Citibank, N.A., a national banking association, as Trustee (the "**Trustee**"), supplements that certain Indenture, dated as of October 15, 2024, by and between the Company and the Trustee (the "**Base Indenture**") as supplemented by the First Supplemental Indenture, dated as of November 4, 2024, by and between the Company and the Trustee (the "**First Supplemental Indenture**").

RECITALS OF THE COMPANY

WHEREAS, the Company has duly authorized, executed and delivered the Base Indenture to provide for the issuance from time to time of its Debt Securities (as defined in the Base Indenture), unlimited as to aggregate principal amount, to bear interest at the rates or formulas, to mature at such times and to have such other provisions as shall be fixed and provided for in the Base Indenture;

WHEREAS, the Company has duly authorized, executed and delivered the First Supplemental Indenture, under which it had issued a series of senior Debt Securities designated as the Company's "6.404% Senior Notes due 2029" (hereinafter called the "**Notes**") pursuant to the terms of the Base Indenture, as supplemented by the First Supplemental Indenture (together, the "**Indenture**") and substantially in the form as set forth in the First Supplemental Indenture;

WHEREAS, Section 9.02 of the Base Indenture provides that, with the consent of the Holders of not less than a majority in aggregate principal amount of the Outstanding Debt Securities of the series affected thereby, the Company and the Trustee may enter into a supplemental indenture for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of the Indenture or of modifying in any manner the rights under the Indenture of the Holders of such Debt Securities, subject to the limitations set forth in the Indenture;

WHEREAS, in accordance with Section 9.02 of the Base Indenture, the Company has received the consent of the Holders of not less than a majority in aggregate principal amount of the Outstanding Notes to amend the Indenture as set forth herein, which consents have not been withdrawn; and

WHEREAS, the Company, by action duly taken, has authorized the execution of this Fourth Supplemental Indenture and all requirements necessary to make this Fourth Supplemental Indenture a valid instrument in accordance with its terms;

NOW, THEREFORE, in consideration of the agreements and obligations set forth herein and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Company and the Trustee, for the benefit of each other and for the equal and ratable benefit of the Holders of the Notes, enter into this Fourth Supplemental Indenture and agree as set forth below, and such parties further agree that this Fourth Supplemental Indenture affects the Company's 6.404% Senior Notes due 2029 only and not any other series of Debt Securities.

------

**ARTICLE I.** 

**DEFINITIONS** 

SECTION 1.1 <u>Certain Terms Defined in the Indenture</u>.

For purposes of this Fourth Supplemental Indenture and the Notes, all capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Indenture, as amended and supplemented hereby.

**ARTICLE II.** 

**AMENDMENTS** 

SECTION 2.1 <u>Amendment and Restatement of Section</u> <u>2.10 of the First Supplemental Indenture</u>.

Section 2.10(b) of the First Supplemental Indenture is hereby amended by adding the phrase "or any UK overseas territory (including but not limited to Bermuda)" immediately after the phrase "or any political subdivision thereof", such that Section 2.10 of the First Supplemental Indenture shall, as amended and restated in its entirety, read as follows:

"SECTION 2.10 <u>Consolidation, Merger or Sale.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The provisions of Section 8.01 of the Indenture shall apply to the Notes, as supplemented by Section 2.10(b) below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) With respect to the Notes only, the following provisions will be added to the end of Section 8.01 of the Indenture and shall apply only to the Notes:

In addition, the Company may not consolidate or merge with or into, or transfer all or substantially all of its assets to, directly or indirectly, to any Person unless either (a) the Company will be the continuing entity or (b) the successor entity or Person to which the Company's assets are transferred is an entity organized under the laws of the United States, any state of the United States or the District of Columbia, or a company organized and existing under the laws of the United Kingdom or any political subdivision thereof or any UK overseas territory (including, but not limited to, Bermuda) or any other country member of the Organisation for Economic Co-operation and Development on the date hereof, and it expressly assumes the Company's obligations on the Notes and under the Indenture. In addition, the Company cannot effect such a transaction unless immediately after giving effect to such transaction, no Default or Event of Default shall have occurred and be continuing. Subject to certain exceptions, when the Person to whom the Company's assets are transferred has assumed the Company's obligations under the Notes and the Indenture, the Company will be discharged from all its obligations under the Notes and the Indenture, except in limited circumstances. Notwithstanding anything in the immediately preceding paragraph, this Section 2.10(b) of this Indenture does not apply to any recapitalization transaction, a change of control of the Company or a highly leveraged transaction, unless the transaction or change of control was structured to include a merger or consolidation or transfer of all or substantially all of the assets the Company.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The provisions of Section 8.03 of the Indenture shall not apply to the Notes."

SECTION 2.2 <u>New Section</u> <u>2.12 of the First Supplemental Indenture</u>.

A new Section 2.12 of the First Supplemental Indenture is hereby added to the First Supplemental Indenture as follows and shall apply to the Notes.

"SECTION 2.12 <u>Assumption of Obligations.</u>

With respect to the Notes only, the following Section 8.04 is hereby added to Article Eight of the Indenture and shall apply only to the Notes:

Section 8.04 Assumption of Obligations by Holding Company of the Group; Substitution of Issuer.

A holding company of the Group (a "Successor Entity") may, without the consent of Holders of the Notes, assume the obligations of the Company (or any corporation which shall have previously assumed the obligations of the Company) for the due and punctual payment of the principal of (and premium, if any, on), or interest on and any additional amount required to be paid in accordance with the provisions of the Indenture, as supplemented by the First Supplemental Indenture and the Fourth Supplemental Indenture, or the Notes and the performance of each covenant of the Indenture, as supplemented by the First Supplemental Indenture and the Fourth Supplemental Indenture, and the Notes on the part of the Company to be performed or observed, *provided*, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) the Successor Entity is an entity organized under the laws of the United States, any state of the United States or the District of Columbia, or a company organized and existing under the laws of the United Kingdom or any political subdivision thereof or any UK overseas territory (including, but not limited to, Bermuda), or any other country member of the Organisation for Economic Co-operation and Development on the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) the Successor Entity shall expressly assume such obligations by an amendment to or supplemental indenture to the Indenture, executed by the Company and such Successor Entity, if applicable, and delivered to the Trustee, in form satisfactory to the Trustee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) such Successor Entity shall confirm in such amendment to or supplemental indenture to the Indenture that it will pay to the Holders all Additional Amounts, if any, payable pursuant to Section 10.04 in respect of the Notes (*provided, however*, that for these purposes such Successor Entity's country of organization will be substituted for the references to the United Kingdom);

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) immediately after giving effect to such assumption of obligations, no Event of Default and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) the Company shall deliver to the Trustee an Officer's Certificate and an Opinion of Counsel stating that all conditions precedent herein provided relating to such assumption have been complied with.

Upon any such assumption, the Successor Entity shall succeed to, and be substituted for, and may exercise every right and power of, the Company under the Indenture with respect to the Notes and the First Supplemental Indenture and the Fourth Supplemental Indenture with the same effect as if such Successor Entity had been named as the Company in the Indenture, the First Supplemental Indenture and the Fourth Supplemental Indenture, and the Company or any legal and valid successor corporation which shall theretofore have become such in the manner prescribed herein, shall be released from all liability as obligor and issuer upon the Notes and such Indenture with respect to the Notes."

**ARTICLE III.** 

**MISCELLANEOUS** 

SECTION 3.1 <u>Relationship with Indenture</u>.

The terms and provisions contained in the Indenture will constitute, and are hereby expressly made, a part of this Fourth Supplemental Indenture. However, to the extent any provision of the Indenture conflicts with the express provisions of this Fourth Supplemental Indenture, the provisions of this Fourth Supplemental Indenture will govern and be controlling.

SECTION 3.2 <u>Trust Indenture Act Controls</u>.

If any provision of this Fourth Supplemental Indenture limits, qualifies or conflicts with another provision which is required to be included in this Fourth Supplemental Indenture by the Trust Indenture Act, the required provision shall control. If any provision of this Fourth Supplemental Indenture modifies or excludes any provision of the Trust Indenture Act which may be so modified or excluded, the latter provision shall be deemed to apply to this Fourth Supplemental Indenture as so modified or to be excluded, as the case may be.

SECTION 3.3 <u>Governing Law</u>.

This Fourth Supplemental Indenture and the Notes shall be governed by and construed in accordance with the laws of the State of New York without regard to conflicts of law principles of such State other than New York General Obligations Law Section 5-1401.

------

SECTION 3.4 <u>Multiple Counterparts</u>.

The parties may sign multiple counterparts of this Fourth Supplemental Indenture. Each signed counterpart shall be deemed an original, but all of them together represent one and the same Fourth Supplemental Indenture. The exchange of copies of this Fourth Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Fourth Supplemental Indenture as to the parties hereto and may be used in lieu of the original Fourth Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. This Fourth Supplemental Indenture shall be valid, binding, and enforceable against a party when executed and delivered by an authorized individual on behalf of the party by means of (i) an original manual signature; (ii) a faxed, scanned, or photocopied manual signature, or (iii) any other electronic signature permitted by the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act, and/or any other relevant electronic signatures law, including any relevant provisions of the Uniform Commercial Code (collectively, "<u>Signature Law</u>"), in each case to the extent applicable. Each faxed, scanned, or photocopied manual signature, or other electronic signature, shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Each party hereto shall be entitled to conclusively rely upon, and shall have no liability with respect to, any faxed, scanned, or photocopied manual signature, or other electronic signature, of any other party and shall have no duty to investigate, confirm or otherwise verify the validity or authenticity thereof. This Fourth Supplemental Indenture may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute one and the same instrument. For the avoidance of doubt, original manual signatures shall be used for execution or indorsement of writings when required under the Uniform Commercial Code or other Signature Law due to the character or intended character of the writings.

SECTION 3.5 <u>Severability</u>.

Each provision of this Fourth Supplemental Indenture shall be considered separable and if for any reason any provision which is not essential to the effectuation of the basic purpose of this Fourth Supplemental Indenture or the Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and a Holder shall have no claim therefor against any party hereto.

SECTION 3.6 <u>Ratification</u>.

SECTION 3.7 <u>Headings</u>.

The Section headings in this Fourth Supplemental Indenture are for convenience only and shall not affect the construction thereof.

SECTION 3.8 <u>Effectiveness</u>.

The provisions of this Fourth Supplemental Indenture shall become effective as of the date hereof.

------

SECTION 3.9 <u>Concerning the Trustee</u>.

In entering into this Fourth Supplemental Indenture, the Trustee shall be entitled to the benefit of every provision of the Indenture relating to the conduct or affecting the liability of or affording protection to the Trustee, whether or not elsewhere herein so provided. The Trustee makes no representations as to the validity, execution or sufficiency of this Fourth Supplemental Indenture other than as to the validity of its execution and delivery by the Trustee. The Trustee assumes no responsibility for the correctness of the recitals contained herein, which shall be taken as a statement of the Company. All of the provisions contained in the Indenture in respect of the rights, privileges, immunities, indemnities, powers, and duties of the Trustee shall be applicable in respect of this Fourth Supplemental Indenture as fully and with like force and effect as though fully set forth in full herein.

*[Remainder of Page Intentionally Left Blank]* 

------

IN WITNESS WHEREOF, the parties hereto have caused this Fourth Supplemental Indenture to be duly executed as of the date first written above.

---

| | |
|:---|:---|
| Marex Group plc | Marex Group plc |
| By: | /s/ Ian Lowitt |
|  | Name: Ian Lowitt |
|  | Title: Chief Executive Officer |

---

[*Signature Page to Fourth Supplemental Indenture*]

------

---

| | |
|:---|:---|
| Citibank, N.A. | Citibank, N.A. |
| By: | /s/ Eva Waite |
|  | Name: Eva Waite |
|  | Title: Senior Trust Officer |

---

[*Signature Page to Fourth Supplemental Indenture*]

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g39300g24s97.jpg)

**Marex Group plc announces successful completion of consent solicitation for its 6.404% Senior Notes due 2029** 

May 18, 2026

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) **–** Marex Group plc (Nasdaq: MRX) ("Marex" or the "Company"), a diversified global financial services platform, announced today that it has received the requisite consents from registered holders of its 6.404% Senior Notes due 2029 (the "Notes") to approve certain proposed amendments (the "Proposed Amendments") to the Indenture, dated as of October 15, 2024 (the "Base Indenture"), as supplemented by the First Supplemental Indenture, dated as of November 4, 2024 (the "First Supplemental Indenture" and, together with the Base Indenture, the "Indenture"), each between Marex and Citibank, NA, as the trustee (the "Trustee"), pursuant to the Company's previously announced solicitation of consents for the Notes (the "Consent Solicitation"). As used in this press release, the term "Group" refers to Marex Group plc, together with its consolidated subsidiaries, as a consolidated entity.

The Consent Solicitation was made pursuant to the terms and conditions set forth in the consent solicitation statement dated May 7, 2026 (the "Consent Solicitation Statement"), and expired at 5:00 p.m., New York City time, on May 15, 2026 (the "Expiration Date"). Subject to the terms and conditions set forth in the Consent Solicitation Statement, holders of the Notes who validly delivered (and did not validly revoke) consents prior to the Expiration Date will receive a cash payment equal to $1.00 per $1,000 principal amount of the Notes (the "Consent Payment") for which such consents were delivered (and not validly revoked). The Company expects to pay such holders the Consent Payment on May 19, 2026 (the "Settlement Date"). Holders who failed to validly deliver (or who validly revoked) their consents on or prior to the Expiration Date will not be entitled to receive the Consent Payment.

On March 26, 2026, Marex announced its proposal to change the legal domicile of its parent holding company to Bermuda from England and Wales (the "Proposed Redomiciliation") and to reorganize the Group. If the requisite shareholder, court and regulatory approvals are obtained, the Proposed Redomiciliation will result in the reorganization of all Group subsidiaries into four regional sub-groups (UK, US, EMEA and Rest of World) under a new Bermuda parent holding company ("New ParentCo").

As previously announced by Marex, consent was sought from holders of the Notes with respect to the Proposed Amendments to align the terms of the Notes and the Indenture with the existing terms of the Company's recently issued 5.680% Senior Notes due 2031 (the "2031 Notes") and the relevant indentures governing the 2031 Notes (the "2031 Notes Indenture"). The Proposed Amendments permit a holding company of the Group that is incorporated in the UK overseas territory of Bermuda, such as New ParentCo, to assume the Company's obligations under the Notes and Indenture, and succeed to, and be substituted for, the Company as issuer and obligor under the Notes and Indenture, in the same manner as such holding company or New ParentCo is permitted under the terms of the 2031 Notes, the Company's 5.829% Senior Notes due 2028 (the "2028 Notes") and other SEC-registered structured notes (the "Structured Notes" and, together with the 2031 Notes and the 2028 Notes, the "Other Existing SEC-Registered Notes") and the relevant indentures governing the Other Existing SEC-Registered Notes (the "Other Existing SEC-Registered Note Indentures") to assume the Company's obligations under the Other Existing SEC-Registered Notes and the Other Existing SEC-Registered Note Indentures, and succeed to, and be substituted for, the Company as issuer and obligor thereunder. If the requisite shareholder, court and regulatory approvals are obtained, then, following the Proposed Redomiciliation, New ParentCo may assume the Notes and, upon such assumption, succeed to and be substituted for Marex Group plc, as obligor under and issuer of the Notes.

------

As reported by the Information and Tabulation Agent, as of the Expiration Date, holders representing in excess of the majority of the outstanding aggregate principal of the Notes validly delivered (and not validly revoked) consents pursuant to the Consent Solicitation. The consents received in the Consent Solicitation are sufficient to effect the Proposed Amendments to the indenture governing the Notes. Accordingly, the Company intends to execute and deliver to the Trustee on the Settlement Date, a fourth supplemental indenture to the Indenture (the "Fourth Supplemental Indenture") to effect the Proposed Amendments. The Proposed Amendments will become effective and operative upon the execution by the Company and Trustee of the Fourth Supplemental Indenture.

Goldman Sachs & Co. LLC acted as the solicitation agent in connection with the Consent Solicitation (the "Solicitation Agent").

Any questions or requests for assistance may be directed to the Information and Tabulation Agent or the Solicitation Agent at their respective telephone numbers or e-mail address set forth below.

The Solicitation Agent for the Consent Solicitation is:

Goldman Sachs & Co. LLC

200 West Street New York, New York 10282

Telephone (U.S. Toll Free): +1 (800) 828-3182

Telephone (U.S. Collect): +1 (212) 902-6351

Telephone (London): +44 207 774 4836

Email: liabilitymanagement.eu@gs.com

Attention: Liability Management Group

The Information and Tabulation Agent for the Consent Solicitation is:

Global Bondholder Services Corporation

65 Broadway, Suite 404

New York, New York 10006

Attention: Corporate Actions

Email: contact@gbsc-usa.com

Banks and Brokers Call: (212) 430-3774

U.S. Toll-Free: (855) 654-2014

International Call: 001-212-430-3774

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

**Forward looking statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, the expected settlement date of the Consent Solicitation. In some cases, these forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions.

------

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation: subdued commodity market activity or pricing levels; the effects of geopolitical events, terrorism and wars, on market volatility, global macroeconomic conditions and commodity prices; our proposed redomiciliation; changes to the U.S. regulatory regime, including with respect to tariffs; changes in interest rate levels or tariffs; the risk of our clients and their related financial institutions defaulting on their obligations to us; regulatory, reputational and financial risks as a result of our international operations; software or systems failure, loss or disruption of data or data security failures; risks associated with the use of artificial intelligence; an inability to adequately hedge our positions and limitations on our ability to modify contracts and the contractual protections that may be available to us in OTC derivatives transactions; market volatility, reputational risk and regulatory uncertainty related to commodity markets, equities, fixed income, foreign exchange and cryptocurrency; the impact of climate change and the transition to a lower carbon economy on supply chains and the size of the market for certain of our energy products; the impact of changes in judgments, estimates and assumptions made by management in the application of our accounting policies on our reported financial condition and results of operations; lack of sufficient financial liquidity; if we fail to comply with applicable law and regulation, we may be subject to enforcement or other action, forced to cease providing certain services or obliged to change the scope or nature of our operations; significant costs, including adverse impacts on our business, financial condition and results of operations, and expenses associated with compliance with relevant regulations; if we fail to remediate the material weaknesses we identified in our internal control over financial reporting or prevent material weaknesses in the future, the accuracy and timing of our financial statements may be impacted, which could result in material misstatements in our financial statements or failure to meet our reporting obligations and subject us to potential delisting, regulatory investigations or civil or criminal sanctions; short seller activity and securities litigation; the inability to realize the anticipated benefits of the Consent Solicitation; the risks discussed under the caption "Certain Significant Considerations" in the Consent Solicitation Statement; and other risks discussed under the caption "Risk Factors" in our 2025 Annual Report on Form 20-F or as updated by any of our subsequent reports filed with the SEC.

The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

**Enquiries please contact:** 

Marex:

Nicola Ratchford / Adam Strachan

+44 778 654 8889 / +1 914 200 2508 \| nratchford@marex.com / astrachan@marex.com

FTI Consulting US / UK

+1 (716) 525-7239 / +44 (0) 7976 870 961 \| marex@fticonsulting.com